Ovidrel Injection, Solution
NDC Package 44087-1150-1

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. NDC HCPCS Crosswalk
    3. Frequently Asked Questions

Package Information

Ovidrel (choriogonadotropin alfa) injection is a medication used as part of a treatment program for certain fertility problems in women. This formulation utilizes a injection, solution delivery system. Marketed by Emd Serono, Inc., this product is identified by NDC 44087-1150 and is authorized under FDA application BLA021149.

Identification & Billing

NDC Package Code
44087-1150-1
Package Description
1 SYRINGE, GLASS in 1 CARTON / .5 mL in 1 SYRINGE, GLASS
Product Code
44087-1150
11-Digit Billing Format
44087115001
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
RxNorm Crosswalk
  • RxCUI: 727505 - choriogonadotropin alfa 250 MCG in 0.5 ML Prefilled Syringe
  • RxCUI: 727505 - 0.5 ML choriogonadotropin alfa 0.5 MG/ML Prefilled Syringe
  • RxCUI: 727505 - choriogonadotropin alfa 0.25 MG per 0.5 ML Prefilled Syringe
  • RxCUI: 727505 - choriogonadotropin alfa 250 MCG per 0.5 ML Prefilled Syringe
  • RxCUI: 727507 - Ovidrel 250 MCG in 0.5 mL Prefilled Syringe

Clinical Specifications

Proprietary Name
Ovidrel
Non-Proprietary Name
Choriogonadotropin Alfa
Substance Name
Choriogonadotropin Alfa
Dosage Form
Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
Administration Route
Subcutaneous - Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.
Active Ingredient(s)
CHORIOGONADOTROPIN ALFA 250 ug/.5mL
Pharmacologic Class
Usage Information
This medication is used as part of a treatment program for certain fertility problems in women. It is generally used in combination with another hormone (FSH). This medication provides the hormone (hCG), which stimulates the release of a mature egg (ovulation) and helps you become pregnant. This medication is not recommended for women whose ovaries no longer make eggs properly (primary ovarian failure). This medication has not been shown to be effective for weight loss and should not be used for this purpose due to risk of serious side effects.

Regulatory & Marketing

Labeler Name
Emd Serono, Inc.
Product Type
Human Prescription Drug
FDA Application #
BLA021149
Marketing Category
BLA - A product marketed under an approved Biologic License Application.
Start Marketing Date
10-06-2003
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Billing & HCPCS Mapping

To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.

J3490
Source: PDAC
UNCLASSIFIED DRUGS
HCPCS Dosage 1 EA
Units / Pkg

Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 44087-1150-1 identifies a specific commercial package of 1 syringe, glass in 1 carton / .5 ml in 1 syringe, glass of Ovidrel, a human prescription drug labeled by Emd Serono, Inc.. This injection, solution is formulated for subcutaneous use and contains choriogonadotropin alfa as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Emd Serono, Inc. on October 06, 2003. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

This medication is used as part of a treatment program for certain fertility problems in women. It is generally used in combination with another hormone (FSH). This medication provides the hormone (hCG), which stimulates the release of a mature egg (ovulation) and helps you become pregnant. This medication is not recommended for women whose ovaries no longer make eggs properly (primary ovarian failure). This medication has not been shown to be effective for weight loss and should not be used for this purpose due to risk of serious side effects.

How is this Emd Serono, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 44087115001. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
44087-1150-1
11-Digit CMS (5-4-2)
44087-1150-01

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.